A 32-year-old woman has relapsing-remitting multiple sclerosis. She experiences recurrent relapses despite first-line disease-modifying therapy. Accor...

Question

A 32-year-old woman has relapsing-remitting multiple sclerosis. She experiences recurrent relapses despite first-line disease-modifying therapy. According to NICE, which drug could be considered a second-line disease-modifying therapy?

Accepted Answer

Alemtuzumab

Answer

Interferon beta-1a

Answer

Glatiramer acetate

Answer

Azathioprine

Answer

Prednisolone

NICE Technology appraisal TA312 on Alemtuzumab MCQ (SBA): Multiple Sclerosis

A 32-year-old woman has relapsing-remitting multiple sclerosis. She experiences recurrent relapses despite first-line disease-modifying therapy. According to NICE, which drug could be considered a second-line disease-modifying therapy?